Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic264 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(BOSS) | withdrawn | Phase 2 | 0 | AstraZenecaINDUSTRY | 0 | Jun 5, 2025 | clinicaltrials |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | withdrawn | Phase 2 | 0 | Inhye AhnOTHER | 0 | May 22, 2025 |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | withdrawn | — | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | withdrawn | Phase 2 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05209308 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL(CORAL) | withdrawn | Phase 2 | 0 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma(BRIO) | withdrawn | Phase 2 | 0 | SecuraBioINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kunming Hope of Health HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | withdrawn | Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | withdrawn | Phase 2 | 0 | Kerry RogersOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02993536 | Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab | withdrawn | — | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Scripps HealthOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | withdrawn | Phase 1 | 0 | Michael ChoiOTHER | 0 | Jan 25, 2019 | clinicaltrials |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02020109 | Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia | withdrawn | — | 0 | Maastricht Radiation OncologyOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01069432 | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia | withdrawn | — | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | withdrawn | Phase 1 | 0 | Molecular Templates, Inc.INDUSTRY | 0 | Mar 2, 2016 | clinicaltrials |
| NCT01739491 | A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia | withdrawn | — | 0 | Janssen PharmaceuticaINDUSTRY | 0 | Dec 2, 2015 | clinicaltrials |
| NCT01271283 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Sep 7, 2012 | clinicaltrials |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 3, 2012 | clinicaltrials |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jul 9, 2012 | clinicaltrials |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | withdrawn | Phase 2 | 0 | CABYCINDUSTRY | 1 | Dec 30, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jun 5, 2025source: clinicaltrials